IMMUNOCORE HLDGS ADS/1 Cash Flow Conversion Efficiency
IMMUNOCORE HLDGS ADS/1 cash flow conversion efficiency. Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has a cash flow conversion efficiency ratio of 0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€15.93 Million ≈ $18.62 Million USD) by net assets (€419.80 Million ≈ $490.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of IMMUNOCORE HLDGS ADS/1 (2022–2025)
Cash flow conversion efficiency of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. This chart illustrates how IMMUNOCORE HLDGS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IMMUNOCORE HLDGS ADS/1 (6YG) share price today for real-time trading data and today's change.
IMMUNOCORE HLDGS ADS/1 Cash Flow Conversion Ratio Explained
IMMUNOCORE HLDGS ADS/1 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
IMMUNOCORE HLDGS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their cash flow conversion efficiency. Also see market value of IMMUNOCORE HLDGS ADS/1 for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
0.029x |
|
Zhejiang Whyis Technology Co.Ltd.
SHE:301218
|
N/A |
|
LIBERTY LAT.AMER.C DL-01
F:1LLC
|
0.434x |
|
Ventec International Group Co Ltd
TW:6672
|
0.025x |
|
Banpu Public Company Limited
BK:BANPU
|
0.016x |
|
Crompton Greaves Consumer Electricals Limited
NSE:CROMPTON
|
0.013x |
|
Godawari Power And Ispat limited
NSE:GPIL
|
0.076x |
|
CTS Corporation
NYSE:CTS
|
0.053x |
Annual Cash Flow Conversion Efficiency for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual cash flow conversion efficiency of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. Review IMMUNOCORE HLDGS ADS/1 free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €381.03 Million ≈ $445.47 Million |
€-10.71 Million ≈ $-12.52 Million |
-0.028x | -138.91% |
| 2024-12-31 | €360.72 Million ≈ $421.71 Million |
€26.06 Million ≈ $30.47 Million |
0.072x | +806.40% |
| 2023-12-31 | €368.84 Million ≈ $431.22 Million |
€2.94 Million ≈ $3.44 Million |
0.008x | +105.49% |
| 2022-12-31 | €338.90 Million ≈ $396.21 Million |
€-49.21 Million ≈ $-57.53 Million |
-0.145x | -- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more